A Study to Assess the Pharmacokinetics, Safety, and Efficacy of Two Doses of Bimekizumab in Adolescent Study Participants With Moderate to Severe Plaque Psoriasis

2상 완료 NCT04718896

요약

The purpose of the study is to assess th pharmacokinetics (PK) of bimekizumab administered subcutaneously (sc) in adolescents with moderate to severe plaque psoriasis (PSO).

Plasma Concentration of Bimekizumab at Week 0

Baseline (Week 0) · microgram per milliliter (µg/mL)

Plasma Concentration of Bimekizumab at Week 1

Week 1 · µg/mL

Plasma Concentration of Bimekizumab at Week 4

Week 4 · µg/mL

BENITIONS에서 보기 ClinicalTrials.gov 원문 보기

같은 질환의 다른 임상

• A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoria — Janssen Pharmaceutical K.K.
• A Study of Guselkumab and Golimumab Combination Therapy in Participants With Active Psoria — Janssen Research & Development, LLC
• A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects Wi — UCB Biopharma SRL
• A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With A — UCB Biopharma SRL
• The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis — Hangzhou Highlightll Pharmaceutical Co., Ltd
• A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis — AbbVie

전체 임상